- « Previous
- Clinical Pharmacology
- Next »
Comvax
Clinical Pharmacology
Comvax
Two clinical studies assessed antibody responses to a three-dose series of COMVAX in 128 evaluable infants who were previously given a birth dose of hepatitis B vaccine. Table 2 summarizes the anti-PRP and anti-HBs responses of these infants. The antibody responses were clinically comparable to those observed in the pivotal trial of COMVAX (Table 1).
Table 2
Antibody Responses to COMVAX in Infants Previously Vaccinated with Hepatitis
B Vaccine at Birth
| Study | Age (months) at Vaccination |
Time | n | Anti-PRP % Subjects with > 0.15 mcg/mL > 1.0 mcg/mL |
Anti-PRP GMT (mcg/mL) |
n | Anti-HBs % Subjects ≥ 10 mIU/mL |
Anti-HBs GMT (mIU/mL) |
|
| Study 1 [N=126] | 2 | Prevaccination Dose 1 | 119 | 24.4 | 5.9 | 0.1 | 71 | 25.4 | 2.9 |
| Not Measured | |||||||||
| 4 | Dose 2* | 111 | 94.6 | 81.1 | 3.3 | 111 | 98.2 | 417.2 | |
| 14/15 | Dose 3* | 88 | 100 | 93.2 | 11.0 0.2 | 87 15 | 98.9 6.7 | 3500.7 | |
| Study 2 [N=19] | Prevaccination | 17 | 58.8 | 0 | 0.7 | ||||
| 2 | Dose 1** | 17 | 88.2 | 47.1 | 0.9 | 16 | 81.3 | 35.2 | |
| 4 | Dose 2** | 17 | 100 | 76.5 | 2.8 | 16 | 100 | 281.8 | |
| 15 | Dose 3** | 15 | 100 | 100 | 8.5 | 16 | 100 | 3913.4 | |
| * Postvaccination responses were determined approximately
2 months after dose 2 and 1 month after dose 3. ** Postvaccination responses were determined approximately 2 months after doses 1, 2, and 3.Infants in these studies received DTP and OPV or eIPV (enhanced inactivated poliovirus vaccine) concomitantly with the first two doses ofCOMVAX, while the third dose of COMVAX was given concomitantly with DTaP (diphtheria and tetanus and acellular pertussis), OPV, andM-M-R* II at 14-15 months of age (Study 1) or with just M-M-R* II at 15 months of age (Study 2). |
|||||||||
Interchangeability of COMVAX and Licensed Haemophilus b Conjugate Vaccines or Recombinant Hepatitis B Vaccines
Generic Name: Haemophilus b Conjugate and Hepatitis B Vaccine
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Living Better
Find the secrets to longer life.
SAM-e for Liver Disease
The supplement SAM-e has been used to treat depression and arthritis. Now researchers are studying whether it can help treat liSee more WebMD Videos »
